Begoña Bermejo de Las Heras

13PUBLICATIONS
188CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|May 10, 2026
Expert consensus on optimal management of liver-related adverse events during CDK4/6 inhibitor therapy.

|Apr 24, 2026
Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

|Jun 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Federico Rojo, Clive R Taylor, Carlos Barrios

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

Pageof 3

Frequent Collaborators

6 joint publications

Manuel Ruíz-Borrego

6 joint publications

Eva Maria Ciruelos Gil

5 joint publications

Miguel J Gil-Gil

4 joint publications

Miguel Martín